Last reviewed · How we verify
Heparine
At a glance
| Generic name | Heparine |
|---|---|
| Sponsor | Hospital General Universitario Gregorio Marañon |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI (Phase 4)
- Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht (N/A)
- Argatroban Versus Lepirudin in Critically Ill Patients - A Randomized Double-blind Trial (Phase 4)
- Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units: A Multicenter Retrospective Cohort Study in the Beaumont Healthcare System (N/A)
- A Study to Determine the Inter/Intra Observer and Intra-Subject Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants (N/A)
- NCT00371020 (Phase 3)
- Outpatient Treatment Of Deep Venous Thrombosis (DVT) Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients (Phase 2)
- Prospective, Randomized, Single Center Study of Atherothrombotic and Thromboembolic Events After Carotid Artery Stenting Using Transfemoral and Transradial Approach (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparine CI brief — competitive landscape report
- Heparine updates RSS · CI watch RSS
- Hospital General Universitario Gregorio Marañon portfolio CI